Pachychoroid and Exudative Maculopathy

Diagnosis and treatment.

By Mark H. Nelson, MD, MBA

Non-CNV Predictors of Success of Anti-VEGF for AMD

Clarifying the role of biomarkers is important in determining prognostic implications.

By Harkaran S. Rana, DO, Daniel F. Kiernan, MD

Biosimilar Therapies in the Treatment of Neovascular AMD

Biosimilar drugs could bring significant cost savings to retina therapy.

By Sruthi Arepalli, MD, Aleksandra V. Rachitskaya, MD

Real-World vs Clinical Trial Data for Retinal Drug Regimens

A Q&A with Charles C. Wykoff, MD

By Jennifer Ford, senior managing editor

Update on Longer-Acting Anti-VEGF Therapies

An expansive horizon is coming into focus.

By Michael A. Singer, MD, Effie Z. Rahman, MD

A Summary of the 48th Annual Aspen Retinal Detachment Society Meeting

By Michael Colucciello, MD

Antiviral Drug Should Not Cause Retinal Toxicity

Screening should not be necessary if drug is given in appropriate doses for a short time.

By Jerry Helzner, contributing editor

Coronavirus Delays Pivotal Retinal Trials

Iveric bio and ProQR announce pauses.

By Jerry Helzner, contributing editor

Regeneron, Genentech Extend Anti-VEGF Payment Terms

In response to the COVID-19 pandemic, both companies have temporarily extended physician payment terms for their anti-VEGF purchases from authorized distributors.

By Jerry Helzner, contributing editor

Retinal Physicians Respond to COVID-19

Maximize safety, communicate with patients, utilize technology, and be prepared.

By Laird Harrison, contributing writer

Topcon Offers Free Breath Shields for Slit Lamps

Breath shield could help prevent spread of coronavirus during eye exams.

By Jerry Helzner, contributing editor

SUBSPECIALTY NEWS: New AMD nomenclature, home-based OCT, prior authorizations, effects of missed ophthalmology visits, and more.

By Jerry Helzner, contributing editor

UPFRONT: History Is Bound to Repeat Itself

This is not just the flu.

By Peter K. Kaiser, MD

CLINICAL TRIAL DOWNLOAD: Data on a Gene Therapy for Dry and Wet AMD

A phase 1 clinical trial program is targeting both disease states.

By Pravin U. Dugel, MD

CODING Q&A: Billing and the New Physician

Start paperwork early to avoid a lapse in payment.

By Suzanne L. Corcoran, COE

NEW PRODUCT APPLICATIONS: Manage Business Operations Efficiently

Platform helps retina practices streamline drug purchasing and inventory management.

By Karen Appold, contributing writer

CLINICAL TRIAL UPDATE

WITH OCT, QUALITY MATTERS

The importance of imager training for proper diagnostics

By Darrin A. Landry, CRA, OCT-C

INTEGRATED IMAGING DELIVERS

How integrated data aids efficiency and better patient care

By Eric W. Schneider, MD

THE GOLD STANDARD OF DME TREATMENT

OCT’s role in the diagnosis and management of diabetic eye disease

By SriniVas R. Sadda, MD

TODAY'S OCT PLATFORMS DRIVE PERSONALIZED AMD CARE

OCT is helping retina specialists improve their diagnostic ability in this critical area

By Peter A. Karth, MD, MBA

THE INTEGRAL ROLE OF OCT IN MANAGEMENT OF MACULAR HOLE

OCT surpasses clinical exam as the most sensitive way to diagnose FTMH

By Christina Y. Weng, MD, MBA

An Eye on Patient Education

Communication is key but unlocking the right combination of tools isn't always easy.

By Eric Butterman, contributing writer